Trials / Unknown
UnknownNCT02839954
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Conditions
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
- Pancreatic Carcinoma
- Triple-Negative Invasive Breast Carcinoma
- Malignant Glioma of Brain
- Colorectal Carcinoma
- Gastric Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-MUC1 CAR-pNK cells |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2018-07-01
- First posted
- 2016-07-21
- Last updated
- 2016-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02839954. Inclusion in this directory is not an endorsement.